Shanghai Henlius CEO Wants To Capitalize On First-Mover Status

Scott Liu Sets Out Ambitions That Go Beyond China

In an exclusive interview with Generics Bulletin, Dr. Scott Liu, co-founder, and CEO of Chinese biosimilars and biologics specialist Shanghai Henlius Biotech, has set out his vision for the firm’s future in China and around the globe.

Liu_Scott_1200
Shanghai Henlius CEO Dr. Scott Liu says the leading Chinese biologics player will seek to capitalize on its first-mover status • Source: Shanghai Henlius Biotech

Almost a year ago, China’s Shanghai Henlius Biotech achieved a major milestone for Chinese biosimilars by obtaining the first approval from the country’s National Medical Products Administration for its rituximab biosimilar, HLX01.

The biosimilar to Roche’s MabThera, for treating non-Hodgkin’s lymphoma, in February 2019 became the first biosimilar to be approved under...

More from Strategy

More from Business